

1 **SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island**  
2 **and remote islands in Okinawa, Japan, 2020-2021.**

3

4 **Authors:**

5 Kenji Mizumoto\*, Yusuke Shimakawa, Yoshiaki Aizawa, Christian Butcher, Naomi

6 Chibana, Mary Collins, Kohei Kameya, Tae Gyun Kim, Satoshi Koyama, Ryota

7 Matsuyama, Melissa M. Matthews, Tomoari Mori, Tetsuharu Nagamoto, Masashi

8 Narita, Ryosuke Omori, Noriko Shibata, Satoshi Shibata, Souichi Shiiki, Syunichi

9 Takakura, Naoki Toyozato, Hiroyuki Tsuchiya, Matthias Wolf, Shuhei Yokoyama, Sho

10 Yonaha, Yoshihiro Takayama

11

12 **Affiliations:**

13 Okinawa Prefecture Epidemiological Statistics and Analysis Committee, Naha-shi,

14 Okinawa, Japan (K. Mizumoto, R. Matsuyama, T. Nagamoto, R. Omori, Y. Shimakawa

15 Y. Takayama); Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of

16 Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan (MM.

17 Matthews, TG. Kim, S. Shibata, N. Shibata, C. Butcher, M. Wolf); Research Support

18 Division, Occupational Health and Safety, OIST, Onna-son, Okinawa, Japan (T.Mori,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 M.Collins); Division of Infectious Diseases, Department of Internal Medicine, Okinawa  
20 Prefectural Chubu Hospital, Uruma-shi, Okinawa, Japan (Y. Takayama, M. Narita, S.  
21 Shiiki, S Takakura, S. Yokoyama, N. Toyozato); Emergency and critical care center,  
22 Okinawa Prefectural Chubu Hospital, Uruma-shi, Okinawa, Japan (N. Toyozato);  
23 Division of Infectious Diseases, Department of Internal Medicine, Okinawa Prefectural  
24 Nambu Medical Center & Children's Medical Center, Haebaru, Shimajiri-gun,  
25 Okinawa, Japan (M. Narita); Department of Emergency and Critical Care Medicine,  
26 Okinawa Prefectural Nambu Medical Center & Children's Medical Center, Haebaru,  
27 Shimajiri-gun, Okinawa, Japan (H. Tsuchiya); Division of Infectious Diseases, Naha  
28 City Hospital, Naha-shi, Okinawa, Japan (N. Chibana), Emergency Department,  
29 Okinawa Prefectural Miyako Hospital, Miyako, Okinawa, Japan (S. Koyama); Division  
30 of Infectious Diseases, Okinawa Prefectural Yaeyama Hospital, Ishigaki, Okinawa,  
31 Japan (K. Kameya); Public Kumejima Hospital, Shimajiri-gun, Okinawa, Japan (Y.  
32 Aizawa, S. Yonaha); Graduate School of Advanced Integrated Studies in Human  
33 Survivability, Kyoto; University Yoshida-Nakaadachi-Cho, Sakyo-Ku, Kyoto-shi,  
34 Kyoto, Japan (K. Mizumoto); Hakubi Center for Advanced Research, Kyoto University,  
35 Yoshidahonmachi, Sakyo-Ku, Kyoto-shi, Kyoto, Japan (K. Mizumoto); Unité  
36 d'Epidémiologie des Maladies Emergentes, Institut Pasteur, 25-28 rue du Docteur Roux,

37 75724 Paris, France (Y. Shimakawa); International Research Center for Medical  
38 Sciences, Kumamoto University, Honjo, Chuo-ku, Kumamoto-shi, Kumamoto, Japan  
39 (Y. Shimakawa); Vaccine Commercialization Center, Gyeongbuk Institute for Bio  
40 industry, Andong, Gyeongbuk, Republic of Korea (TG. Kim);  
41 Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima,  
42 Japan (R. Matsuyama); International Institute for Zoonosis Control, Hokkaido  
43 University, Sapporo, Hokkaido, Japan (R. Omori); Division of Bacteriology,  
44 Department of Microbiology and Immunology, Faculty of Medicine, Tottori University,  
45 Yonago, Tottori, Japan (N. Shibata, S. Satoshi); Department of International Health and  
46 Medical Anthropology, Institute of Tropical Medicine, Nagasaki University, Nagasaki,  
47 Nagasaki, Japan (Y. Takayama)

48

49 \*Corresponding author

50 Email: [mizumoto.kenji.5a@kyoto-u.ac.jp](mailto:mizumoto.kenji.5a@kyoto-u.ac.jp) (KM)

51 **Article type:**

52 Original Research

53 **Word count:**

54 Abstract: 353 (Max 300)

## 55 **Abstract**

56           We estimated the seroprevalence of anti-SARS-COV-2 IgG in different island  
57 groups in Okinawa and described its changes over time. A cross-sectional sero-survey  
58 was repeated in three distinct periods between July 2020 and February 2021. A total of  
59 2683 serum samples were collected from six referral medical centers, each covering a  
60 separate region in Okinawa. Patients who visited the emergency department for any  
61 reason and underwent blood collection were eligible for the study. Samples were  
62 analyzed using an FDA-authorized two-step enzyme-linked immunosorbent assay  
63 (ELISA) protocol. The case detection ratio was computed by dividing the  
64 seroprevalence by the attack rate obtained from publicly available surveillance data. In  
65 the main island, the seroprevalence was 0.0% (0/392, 95% CI: 0.0-0.9), 0.6% (8/1448,  
66 0.2-1.1), and 1.4% (8/582, 0.6-2.7) at the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> sero-survey, respectively. In  
67 the remote islands, the seroprevalence was 0.0% (0/144, 95% CI: 0.0-2.5) and 1.6%  
68 (2/123, 0.2-5.8) at the 2<sup>nd</sup> and 3<sup>rd</sup> survey, respectively. The overall case detection ratios  
69 at the 3<sup>rd</sup> survey were 2.7 (95% CI: 1.3-5.3) in the main island and 2.8 (0.7-11.1) in the  
70 remote islands. The highest age-specific case detection ratio was observed in people  
71 aged 20-29 years (8.3, 95% CI: 3.3-21.4) in the main island and in those aged 50-59  
72 years (14.1, 2.1-92.7) in the remote islands. The low seroprevalence at the latest survey

73 suggested that a large-scale epidemic had not yet occurred in Okinawa by February  
74 2021. The case detection ratios imply that the cumulative number of incident cases in  
75 Okinawa should be 2-3 times higher than that reported by routine surveillance. The ratio  
76 was particularly high in young people probably due to a frequent asymptomatic/mild  
77 COVID-19 disease in this age group. To accurately measure the scale of the COVID-19  
78 epidemic, it is crucially important to conduct a sero-survey targeting the young.  
79

## 80 **Introduction**

81           Since the first case of COVID-19 in Japan was reported on February 14, 2020,  
82   Okinawa Prefecture has faced a total of six waves of COVID-19 as of January 10, 2022,  
83   with a total of 58209 cases and 398 deaths, compared to 395 patients and seven deaths as  
84   of July 31, 2020, when the sero-epidemiological survey was initially planned [1].  
85   Okinawa Prefecture consists of a large number of remote islands centered around the  
86   Okinawa Main Island in a vast ocean area. Due to limited medical resources in the remote  
87   islands, the dynamics of the COVID-19 epidemic, once it spreads, may differ greatly  
88   between the Main Island and the remote islands, including the need for transfer of patients  
89   to the larger well-resourced islands by air or sea depending on the case load and clinical  
90   severity of the patients at hand.

91           Since most infected individuals remain mild or asymptomatic, it is widely  
92   accepted that the volume of unreported cases of COVID-19 is substantial. Previous  
93   studies have reported that the proportion of asymptomatic infections among the elderly  
94   groups can reach about 20 percent [2-3]. Despite many mild cases, some may progress to  
95   severe diseases resulting in an estimated infection fatality ratio of as high as 6.4% in  
96   people over 70 years old [4-6]. Given this high unreported proportion and the poor  
97   prognosis for a subset of patients, it is essential to repeat serological surveys over time to

98 obtain a complete picture of the disease dynamics and burden caused by COVID-19. The  
99 proportion of previously infected people is a useful indicator to assess the unreported and  
100 ascertainment bias regarding the number of cases notified through a surveillance system,  
101 the true incidence rate of severe disease and mortality, and the degree of herd immunity.

102

103 Large-scale sero-epidemiological surveys have been conducted worldwide, including in  
104 Spain and Switzerland, since the first wave of the COVID-19 pandemic [7-8]. In Japan,  
105 when this sero-epidemiological survey was originally planned for 2020, there were  
106 already a few serosurveys that have been conducted. But these were limited to urban  
107 settings (Tokyo, Miyagi, and Osaka) [9] or to a single hospital or private company [10-  
108 11].

109 To the best of our knowledge, this is the first sero-epidemiological survey  
110 targeting a wide rural population in Japan. The objective was to determine the  
111 seroprevalence of SARS-COV-2 infection in different island groups in Okinawa and to  
112 capture the increase in the number of infected residents over time using statistical methods.

113

## 114 **Materials and methods**

### 115 **Study setting**

116 Okinawa Prefecture is located on the southwestern tip of the Japanese  
117 archipelago, and it consists of over 160 large and small islands, including about 50  
118 inhabited islands over a vast ocean area. These islands are divided into Okinawa Main  
119 Island and geographically distinct smaller archipelagos such as the Miyako Islands,  
120 Yaeyama Islands, and others (Fig 1). Of the approximately 1.45 million people in  
121 Okinawa Prefecture, the Main Island accounts for about 1.32 million (91%) and the  
122 outlying islands for 130,000 (9%).

123

124 **Fig 1. Location of Okinawa Prefecture and six healthcare facilities participated in**  
125 **the study.**

126 Six healthcare facilities participated in the study: Okinawa Prefectural Chubu  
127 Hospital (C), Okinawa Prefectural Nambu Medical Center & Children's Medical Center  
128 (NMC), Naha City Hospital (NC), Okinawa Prefectural Miyako Hospital (M), Okinawa  
129 Prefectural Yaeyama Hospital (Y), and Public Kumejima Hospital (K). These were  
130 selected because they represent a referral medical center located in each region of  
131 Okinawa, as presented with red dots in Fig 1. The former three hospitals are tertiary



132 medical institutions located on Okinawa Main Island, and the latter three are secondary

133 hospitals located in Miyako Island, Ishigaki Island, and Kumejima Island, respectively.

134

## 135 **Study design**

136 We conducted a repeated cross-sectional survey in three distinct periods: the 1<sup>st</sup>

137 survey period was from July 1, 2020, to July 31, 2020, the 2<sup>nd</sup> survey period was from

138 October 1, 2020, to December 31, 2020, and the 3<sup>rd</sup> survey period was from February 1,

139 2021, to February 28, 2021. In remote islands, survey was conducted only in the 2<sup>nd</sup> and

140 3<sup>rd</sup> survey periods. This study was a prospective observational study and carried out on

141 an opt-out basis, with relevant disclosures about the study on the prefectural website

142 and informational posters displayed at each institution. All patients who visited and

143 underwent blood collection for any reason at the emergency departments during these

144 periods were included in this study unless they explicitly chose to be excluded. The

145 remnant leftover serum samples and anonymized demographic data, age group and sex,

146 obtained from medical records were systematically collected. Personal identifiers and

147 identification numbers linking serum samples with medical records were only

148 accessible by a dedicated physician in charge of patient care at each hospital. Serum

149 samples were shipped to Okinawa Institute of Science and Technology Graduate

150 University (OIST), where the serology testing was performed. All the samples were  
151 analyzed centrally at OIST using an FDA-authorized 2-step ELISA protocol [12], which  
152 detected antibodies against recombinant spike protein purified from mammalian cell  
153 culture at OIST.

154

## 155 **Sample size calculation**

156 We defined the sample size for each study period to ensure the precision of an  
157 estimate. Assuming a prevalence of 0.5%, recruiting 2,124 people in each period would  
158 result in a 95% confidence interval (95%CI) of  $\pm 0.3\%$ .

159

## 160 **Antibody measurements**

161 The samples were tested with the FDA-authorized Mount Sinai SARS-CoV-2  
162 2-step ELISA protocol [12], which has a documented sensitivity of 92.5% and  
163 specificity of 100% [13]. Briefly, sera diluted 1:50 were tested against SARS-CoV-2  
164 receptor binding domain (RBD). Samples reactive against RBD were tested again by 3-  
165 fold serial dilution from 1:100 against full-length, trimeric SARS-CoV-2 spike protein  
166 (original Wuhan variant). True positives were defined as samples having signal

167 intensity higher than their plate threshold for both RBD-coated ELISA and for the first  
168 two dilutions of the spike-coated ELISA. Plate threshold was defined as 4 times the  
169 average of the no serum internal controls (on average 0.19AU).

## 170 **Epidemiological data**

171 Serological data collected in C, NMC, and NC were classified as “Okinawa  
172 Main Island”, and those collected in M, Y, and K were classified as “remotes islands”.  
173 We generated daily time series data of COVID-19 patients for the Okinawa Main Island  
174 and remote islands using data obtained from the Okinawa Prefecture about confirmed  
175 cases with the date of a confirmed diagnosis, age group, and the municipality of  
176 residence, from January 2020 to March 2021. A total of 41 cities, towns, and villages in  
177 Okinawa Prefecture are divided into six areas according to the jurisdiction of the public  
178 health center: Northern, Central, Southern, Naha City, Miyako, and Yaeyama. In this  
179 study, 15 municipalities that are not located on the main island were classified as  
180 “remote islands” from a geographical perspective. These are all municipalities under the  
181 jurisdiction of the Yaeyama and Miyako Public Health Centers, Ie Village, Iheya  
182 Village, and Izena Village under the jurisdiction of the Northern Public Health Center,  
183 and Tokashiki Village, Zamami Village, Aguni Village, Tonaki Village, Minami Daito  
184 Village, Kita Daito Village, Kumejima Town, and Yaese Town under the jurisdiction of

185 the Southern Public Health Center. The population size by age group and municipality  
186 as of January 1, 2020, was obtained from the public source and categorized into  
187 Okinawa Main Island and remote islands and by age group [14].

## 188 **Statistical analysis**

189 The attack rate was calculated by the number of cumulative confirmed cases  
190 divided by the total number of the population. Case detection ratio was defined as a  
191 ratio of seroprevalence to attack rate [9]. In order to take into account a latency period  
192 between the exposure to the virus and the development of IgG antibodies, we used the  
193 attack rate of two weeks before the end of each serosurvey for the calculation of the  
194 case detection ratio [15]. Confidence intervals for seroprevalence and attack rates were  
195 obtained using the exact binomial test.

196 All statistical analyses were conducted using R version 4.1.0 (R Foundation for  
197 Statistical Computing, Vienna, Austria).

198

## 199 **Results**

200 The number of serum samples collected in the Main Island was 392, 1442, and  
201 582, at the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> survey period, respectively. In remote islands, a total of 144

202 and 123 serum samples were collected at the 2<sup>nd</sup> and 3<sup>rd</sup> survey period, respectively.

203 There were no duplicate samples collected from the same individual across the study

204 periods.

205 Table 1 presented the prevalence of IgG anti-SARS-CoV-2 in Main Island and

206 remote islands for each survey period by age group (0-9, 10-19, 20-29, 30-39, 40-49,

207 50-59, 60-69, 70-79, and ≥80 years old), by wide age category (0-19, 20-59, ≥60 years

208 old), and by gender. The age-specific seroprevalences at each period are also presented

209 in Fig 2.

210

211 **Table 1 –Patient characteristics and the number of positive cases by survey period**

212 **stratified by regions, Okinawa, 2020-2021.**

	Main island									Remote islands								
	1 <sup>st</sup>			2 <sup>nd</sup>			3 <sup>rd</sup>			1 <sup>st</sup>			2 <sup>nd</sup>			3 <sup>rd</sup>		
	N	Positive	%Positive (95%CI)	N	Positive	%Positive (95%CI)	N	Positive	%Positive (95%CI)	N	Positive	%Positive (95%CI)	N	Positive	%Positive (95%CI)	N	Positive	%Positive (95%CI)
Total	392	0	0.0 (0.0-0.9)	1448	8	0.6 (0.2-1.1)	582	8	1.4 (0.6-2.7)	NA	NA	NA	144	0	0.0 (0.0-2.5)	123	2	1.6 (0.2-5.8)
Age group																		
0-9	6	0	0.0 (0-45.9)	33	0	0.0 (0.0-10.6)	7	0	0.0 (0.0-41.0)	NA	NA	NA	0	0	NA	0	0	NA
10-19	12	0	0.0 (0-26.5)	60	0	0.0 (0.0-6.0)	26	0	0.0 (0.0-13.2)	NA	NA	NA	5	0	0.0 (0.0-52.2)	5	0	0.0 (0.0-52.2)
20-29	31	0	0.0 (0-11.2)	83	0	0.0 (0.0-4.3)	48	4	8.3 (2.3-20.0)	NA	NA	NA	4	0	0.0 (0.0-60.2)	6	0	0.0 (0.0-45.9)
30-39	45	0	0.0 (0-7.9)	134	0	0.0 (0.0-2.7)	44	0	0.0 (0.0-8.0)	NA	NA	NA	2	0	0.0 (0.0-84.2)	12	0	0.0 (0.0-26.5)
40-49	42	0	0.0 (0-8.4)	144	2	1.4 (0.2-4.9)	51	0	0.0 (0.0-7.0)	NA	NA	NA	9	0	0.0 (0.0-33.6)	10	0	0.0 (0.0-30.8)
50-59	49	0	0.0 (0-7.3)	190	2	1.1 (0.1-3.8)	60	1	1.7 (0.0-8.9)	NA	NA	NA	17	0	0.0 (0.0-19.5)	12	1	8.3 (0.2-38.5)
60-69	63	0	0.0 (0-5.7)	193	0	0.0 (0.0-1.9)	89	2	2.2 (0.3-7.9)	NA	NA	NA	24	0	0.0 (0.0-14.2)	20	0	0.0 (0.0-16.8)
70-79	60	0	0.0 (0-6.0)	255	1	0.4 (0.0-2.2)	100	1	1.0 (0.0-5.4)	NA	NA	NA	21	0	0.0 (0.0-16.1)	16	0	0.0 (0.0-20.6)
Over 80	84	0	0.0 (0-4.3)	356	3	0.8 (0.2-2.4)	157	0	0.0 (0.0-2.3)	NA	NA	NA	62	0	0.0 (0.0-5.8)	42	1	2.4 (0.1-12.6)
Age category																		
Child (0-19)	18	0	0.0 (0.0-18.5)	93	0	0.0 (0.0-3.9)	33	0	0.0 (0.0-10.6)	NA	NA	NA	5	0	0.0 (0.0-52.2)	5	0	0.0 (0.0-52.2)
Adult (20-59)	167	0	0.0 (0.0-2.2)	551	4	0.7 (0.2-1.8)	203	5	2.5 (0.8-5.7)	NA	NA	NA	32	0	0.0 (0.0-10.9)	40	1	2.5 (0.1-13.2)

Senior (over 60)	207	0	0.0	804	4	0.5	346	3	0.9	NA	NA	NA	107	0	0.0	78	1	1.3
			(0.0-1.8)			(0.1-1.3)			(0.2-2.5)						(0.0-3.4)			(0.0-6.9)
Gender																		
Female	217	0	0.0	759	5	0.7	301	5	1.7	NA	NA	NA	68	0	0.0	51	1	2.0
			(0.0-1.7)			(0.2-1.5)			(0.5-3.8)						(0.0-5.3)			(0.0-10.4)
Male	175	0	0.0	689	3	0.4	281	3	1.1	NA	NA	NA	76	0	0.0	72	1	1.4
			(0.0-2.1)			(0.1-1.3)			(0.2-3.1)						(0.0-4.7)			(0.0-7.5)

213 CI: Confidence intervals, ‡Upper and lower 95% confidence interval

214

215 **Fig 2. SARS-CoV-2 IgG seroprevalence by age group in Okinawa Main Island and**

216 **remote islands during the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> survey periods, Japan, 2020-2021. (A)**

217 Main Island, 1<sup>st</sup> survey period, (B) Main Island, 2<sup>nd</sup> survey period, (C) Main Island, 3<sup>rd</sup>

218 survey period, (D) remote islands, 2<sup>nd</sup> survey period, (E) remote islands, 3<sup>rd</sup> survey

219 period. There is no available data for under 10 years old in those age in the 2<sup>nd</sup> and 3<sup>rd</sup>

220 survey periods in the remote islands.

221

222 The seroprevalence in Main Island was 0.0% (0/392, 95%CI: 0.0-0.9%) for the

223 1<sup>st</sup> survey period, 0.6% (8/1448, 95%CI: 0.2-1.1%) for the 2<sup>nd</sup> survey period, and 1.4%

224 (8/582, 95%CI: 0.6-0.7%) for the 3<sup>rd</sup> survey period. In remote islands the

225 seroprevalence was 0.0% (0/144, 95%CI: 0.0-2.5%) for the 2<sup>nd</sup> survey period and 1.6%

226 (2/123, 95%CI: 0.2-5.8) for the 3<sup>rd</sup> survey period.

227 In Main Island, seroprevalence was taking the average value of zero with

228 different upper 95%CI for all subgroups in age group, age category, and gender for the

229 1<sup>st</sup> survey period. For the 2<sup>nd</sup> survey period, some subgroups were taking the average  
230 positive values. They were: those aged 40-49 year-old, 1.4% (95%CI: 0.2-4.9%); those  
231 aged 50-59 year-old, 1.1% (95%CI: 0.1-3.8%); those aged 70-79 year-old, 0.4%  
232 (95%CI: 0.2-2.2%); and those aged 80 years and above, 0.8% (95%CI: 0.2-2.4%). By  
233 age category, it was 0.0% (95%CI: 0.0-3.9%) for children aged 0-19 years, 0.7%  
234 (95%CI: 0.2-1.8%) for adults aged 20-59 years, and 0.5% (95%CI: 0.1-1.3%) for  
235 seniors aged 60 years and over. By gender, it was 0.7% (95%CI: 0.2-1.5%) for female,  
236 and 0.4% (95%CI: 0.1-1.3%) for male.

237 Finally, for the 3<sup>rd</sup> survey period, the seroprevalences had seen an increase  
238 relative to those in the previous survey periods. The age-specific prevalence was 8.3  
239 (95%CI: 2.3-20.0%) for 20-29 years-old; 1.7 % (95%CI: 0.0-8.9%) for 50-59 years-  
240 olds; 2.2 (95%CI: 0.3-7.9%) for 60-69 years-old; and 1.0% (95%CI: 0.0-5.4%) for 70-  
241 79 years-old.

242 By using wider age category, the prevalence was 0.0% (95%CI: 0.0-10.6%) for  
243 children, 2.5% (95%CI: 0.8-5.7%) for adults, and 0.9 % (0.2-2.5%) for seniors. The  
244 sex-specific prevalence was 1.7% (95%CI: 0.5-3.8%) for female and 1.1% (95%CI: 0.2-  
245 3.1%) for male.

246 In remote islands, seroprevalence was taking the average value of zero with

247 different uncertainty bounds for all subgroups in age group, age category, and gender  
248 for the 2<sup>nd</sup> survey period. For the 3<sup>rd</sup> survey period, some subgroups were taking the  
249 average positive values: 8.3% (95%CI: 0.2-38.5%) for those aged 50-59 year-old and  
250 2.4% (95%CI: 0.1-12.6%) for those aged 80 years and above.

251 By using wider age category, the prevalence was 0.0% (95%CI: 0.0-52.2%) for  
252 children, 2.5% (95%CI: 0.1-13.2%) for adults and 1.3 % (0.0-6.9%) for seniors. The  
253 sex-specific prevalence was 2.0% (95%CI: 0.0-10.4%) for female and 1.4% (95%CI:  
254 0.0-7.5%) for male.

255 Fig 3 presented the attack rates in Main Island and remote islands by age  
256 groups at three distinct time points: July 15, 2020; November 15, 2020; and February  
257 15, 2021. These are intermediate time points for corresponding survey periods.  
258 Temporal distributions of confirmed cases and cumulative confirmed cases in Main  
259 Island and remote islands were presented in Fig 4, where three study periods were  
260 highlighted in grey.

261

262 **Fig 3. Attack rates of COVID-19 by age group in Okinawa Main Island and**  
263 **remote islands during the 1st, 2nd, and 3rd survey periods, Japan, 2020-2021. (A)**  
264 Main Island, 1st survey period, (B) Main Island, 2nd survey period, (C) Main Island,



265 3rd survey period, (D) remote islands, 2nd survey period, (E) remote islands, 3rd survey  
266 period.

267

268 **Fig 4. Temporal distribution of COVID-19 cases by Okinawa Main Island and**  
269 **remote islands, Okinawa Prefecture in Japan, March 2020- March 2021.** Incidence  
270 cases in (A) Main Island and (B) Remote islands over time. Cumulative cases in (C)  
271 Main Island and (D) Remote islands over time. As the dates of illness onset were not  
272 available, we used dates of confirmation.

273

274 The overall case detection ratios were 2.2 (95%CI: 1.1-4.4) for the 2<sup>nd</sup> survey  
275 period and 2.7 (95%CI: 1.3-5.3) for the 3<sup>rd</sup> survey period in Main Island, and 2.8  
276 (95%CI: 0.7-11.1) for the 3<sup>rd</sup> survey period in remote islands. Due to the insufficient  
277 number of seropositive cases, the case detection ratio was not obtained for the 1<sup>st</sup> survey  
278 period in Main Island and 2<sup>nd</sup> survey period in remote islands. We then investigated  
279 which age groups had a relatively high case detection ratio. In the 2<sup>nd</sup> survey period in  
280 the Main Island, the highest and second-highest age-specific case detection ratios were  
281 observed in the age group of 40-49 years (4.6, 95%CI: 1.2-18.2), 50-59 years (3.7,  
282 95%CI: 0.9-14.6) and 80-89 years (3.7, 95%CI: 1.2-11.4). In the 3<sup>rd</sup> survey period in the

283 Main Island, the age-specific case detection ratio was the highest in the age group of 20-  
284 29 years (8.3, 95%CI: 3.3-21.4), followed by those aged 60-69 years (4.5, 95%CI: 1.2-  
285 17.9). In the 3<sup>rd</sup> survey period in the remote islands, the ratio was the highest in the age  
286 group of 50-59 years (14.1, 95%CI: 2.1-92.7), followed by those aged  $\geq 80$  years (3.0,  
287 95%CI: 0.4-21.0).

288

## 289 **Discussion**

290 By repeating sero-epidemiological surveys at three different periods between  
291 2020 and 2021, we obtained the estimates of the proportion of previously infected  
292 people in Okinawa Main Island and remote islands. The study findings suggested that  
293 the majority of the local population in Okinawa Island were not infected with SARS-  
294 CoV-2 as of February 2021. This implies that a large-scale epidemic had not yet  
295 occurred. In addition, the estimated seroprevalence among the elderly over 60 years old  
296 was relatively low. Although there may have been fewer opportunities for social  
297 activities that put the elderly at risk of infection, early communication of the high  
298 mortality rate among infected elderly through the media may have led to a behavior of  
299 the elderly people and their careers in favor of preventing the infection [4]. In Japan,  
300 priority was given to the vaccination of health care workers and then the elderly against

301 the COVID-19. The vaccination of healthcare workers and elderly people started on  
302 February 17, 2021, and April 12, 2021, respectively[16]. Given that the last survey  
303 period was until February 28, 2021, local population, except for a very small number of  
304 health care workers, had not been vaccinated during the study period. Our observation  
305 that the most of the survey participants were susceptible to the infection supports the  
306 rationale for prioritizing elder population, who are at higher risk of death, for  
307 vaccination as a public health policy in Japan.

308         The seroprevalence of 0.0% (0/392, 95% CI: 0.0-0.9%) in July 2020 in the  
309 Okinawa Main Island was quite similar to the seroprevalence of 0.0% (1/3009, 95% CI:  
310 0.0-0.2) in Miyagi Prefecture in early June 2020, which was known to have a relatively  
311 low attack rate of 0.004% (88 cases/2.3 million population) as of May 31, 2020 (9). We  
312 expected that the seroprevalence in Okinawa in the 1<sup>st</sup> survey should be higher than that  
313 in Miyagi Prefecture for two reasons. First, the attack rate in Okinawa Prefecture as of  
314 May 31 was 0.010% (142 cases/1.4 million people), which is about 2.5 times higher  
315 than that in Miyagi Prefecture. Second, the study setting in Okinawa's serosurvey was  
316 emergency outpatient, while in Miyagi's serosurvey this was a random sample from the  
317 civil registry. Possible reasons for this unexpectedly low seroprevalence rate in our  
318 study in Okinawa include the insufficient sample size in the serosurvey and a potential

319 for selection bias due to a difference in the risk of infection between the general  
320 population and those visiting in the emergency departments.

321 The prefectural-level case detection ratios that ranged from 2.2 to 2.8 in our  
322 study were similar to those obtained in other parts of Japan during the same period (2.6-  
323 8.7) and considerably lower than those reported in Switzerland ( $\approx$ 20-50) [9, 17]. These  
324 results suggest that the surveillance system in Japan may capture the actual number of  
325 incident cases better than other countries. The expansion of the PCR testing capacity  
326 and monitoring system during a pandemic represents a key intervention, and we believe  
327 that the Okinawa Prefecture was moderately well prepared in the PCR screening and  
328 monitoring system to grasp the actual status of the epidemic. In the 2<sup>nd</sup> survey period,  
329 when the spread of the epidemic was still limited, the case detection ratios of middle-  
330 aged and older people were higher than those in younger age groups. However, in the  
331 3<sup>rd</sup> survey period, when the epidemic spread more widely, the detection ratios of people  
332 in the age group of 20-29 years were much higher than those in other age-groups. Since  
333 the vast majority of young people have asymptomatic or mild disease, it is likely that  
334 many of them do not come for testing. To get a complete picture of the epidemic, PCR  
335 testing and monitoring systems need to be expanded, especially to improve access to  
336 testing and care for young people.

337           In the remote islands, the characteristics of the distribution of the attack rate  
338 were similar to those of the Main Island, especially in the 3<sup>rd</sup> period when the epidemic  
339 was widespread. However, because we could not obtain enough samples in the  
340 serological survey, the uncertainty bounds were quite wide, and we were not able to  
341 obtain precise estimates. More participants would have been needed to accurately  
342 estimate the burden of COVID-19. We also had a sample of 33 people in their 50s or  
343 younger in the midst of the epidemic, but none were positive. Young people are  
344 healthier and less likely to visit emergency departments.

345           The number of confirmed cases among young people was low in 2020 but  
346 increased in early 2021. It has been pointed out that the small number of young people  
347 in 2020 may be due to measurement bias, where testing was not conducted in low-risk  
348 young people because of insufficient testing systems. However, in the present study, the  
349 low serological positivity rate among young people in the early stage of the 2020  
350 outbreak suggests the possibility that the COVID-19 was not actually prevalent among  
351 young people, rather than measurement bias.

352           Our study has limitations. As with other serological studies, our current study  
353 is not entirely free of selection bias. The age distribution of the general population and  
354 that of healthcare-seeking patients at emergency departments should be quite different.

355 Indeed, the age distribution of participants in the current analysis was skewed towards  
356 older people, potentially impacting the overall estimates of seroprevalence.  
357 Furthermore, emergency outpatients may not accurately represent the local population  
358 in terms of the risk of exposure to COVID-19 and preventive behaviors, including the  
359 uptake of the vaccine. This “unrepresentativeness” may be more prominent in secondary  
360 care hospitals, where disease severity is high. The survey period differed somewhat  
361 among the six facilities. This may have had some effects on the results.

362

## 363 **Conclusion**

364 In conclusion, this study revealed that the majority of the local population in  
365 Okinawa was still susceptible to the COVID-19 disease, indicating that a large-scale  
366 epidemic had not yet occurred among residents in Okinawa Prefecture. When the spread  
367 of the epidemic materializes, high-intensity countermeasures would be required,  
368 focusing primarily on the elderly, who are at high risk of death. Furthermore, it was  
369 shown that as the epidemic progresses, the case detection ratio would be higher among  
370 younger people, who have a higher proportion of asymptomatic and mild cases and do  
371 not actively seek testing. The Omicron variant, which is currently spreading globally,  
372 apparently has an even higher rate of mild illness than the previous strains, particularly

373 among young people; this indicates that the number of reported cases might hugely  
374 underestimate the current incidence of the infection. In order to accurately measure the  
375 scale of the COVID-19 epidemic, it is crucially important to conduct a serological  
376 survey targeting the young age group.

377

### 378 **Availability of data and materials**

379 The data that support the findings of this study are available from the corresponding  
380 author (Dr. Kenji Mizumoto) and Okinawa Prefecture Government, but restrictions apply  
381 to the availability of these data, which were used under license for the current study, and  
382 so are not publicly available. Data are however available from the authors upon  
383 reasonable request and with permission of Okinawa Prefecture Government.

384

### 385 **List of abbreviations**

386 COVID-19: Coronavirus Disease 2019

387 RT-PCR: Reverse Transcription Polymerase Chain Reaction

388 SARS-CoV-2: Severe Acute Respiratory Syndrome Virus 2

## 389 **Acknowledgments**

390 Authors appreciate the following institutions for their contribution to support this study:

391 Okinawa Prefecture, Sanitary and Environmental Research Institute in Okinawa

392 Prefecture, Public Health Centers, Public Health Institutes, and medical facilities in

393 Okinawa Prefecture.

394

## 395 **References**

396 1. (NHK) JBC. Special Site: New Coronavirus [cited 2021 9/30]. Available from:

397 <https://www3.nhk.or.jp/news/special/coronavirus/data/>.

398 2. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic

399 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond

400 Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10).

401 3. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al.

402 Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).

403 Int J Infect Dis. 2020;94:154-5.

404 4. Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al.

405 Estimating the infection and case fatality ratio for coronavirus disease (COVID-19)



- 406 using age-adjusted data from the outbreak on the Diamond Princess cruise ship,  
407 February 2020. *Euro Surveill.* 2020;25(12).
- 408 5. Munayco C, Chowell G, Tariq A, Undurraga EA, Mizumoto K. Risk of death by age  
409 and gender from CoVID-19 in Peru, March-May, 2020. *Aging (Albany NY).*  
410 2020;12(14):13869-81.
- 411 6. Undurraga EA, Chowell G, Mizumoto K. COVID-19 case fatality risk by age and  
412 gender in a high testing setting in Latin America: Chile, March-August 2020. *Infect*  
413 *Dis Poverty.* 2021;10(1):11.
- 414 1. 7. To KK, Cheng VC, Cai JP, Chan KH, Chen LL, Wong LH, et al. Seroprevalence  
415 of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province,  
416 China: a multicohort study. *Lancet Microbe.* 2020;1(3):e111-e8.
- 417 7. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda  
418 M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,  
419 population-based seroepidemiological study. *Lancet.* 2020;396(10250):535-44.
- 420 8. Yoshiyama T, Saito Y, Masuda K, Nakanishi Y, Kido Y, Uchimura K, et al.  
421 Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020. *Emerg Infect*  
422 *Dis.* 2021;27(2):628-31.

- 423 9. Nakamura A, Ando S, Endo H, Sato R. Seroprevalence of antibodies to SARS-CoV-  
424 2 in healthcare workers in a non-epidemic region, Japan: A hospital-based study on  
425 May, 2020. *J Med Virol.* 2021;93(7):4608-11.
- 426 10. Corp. SG. Preliminary results of antibody tests. SoftBank Group Corp.; 2021  
427 2020/6/9.
- 428 11. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et  
429 al., SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological  
430 Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* 57 (2020),  
431 doi:10.1002/cpmc.100.
- 432 12. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MR, Mansour M, et al. Robust  
433 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science.*  
434 2020;370(6521):1227-1230.
- 435 13. Prefecture O. Basic Resident Ledger Population by Age 2021 [Available from:  
436 <https://www.pref.okinawa.jp/site/kikaku/shichoson/2422.html>].
- 437 14. National Institute of Infectious Disease J. Evaluation of anti-SARS-CoV-2 antibody  
438 in blood by rapid and simple detection method (immunochromatography). National  
439 Institute of Infectious Disease, Japan; 2020 2020/4/1.

440 15. Japan PMsOo. COVID-19 vaccination schedule in JAPAN 2022 [cited 2022 1/25].

441 Available from:

442 [https://www.kantei.go.jp/jp/headline/kansensho/vaccine\\_supply.html](https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html).

443 16. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al.

444 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland

445 (SEROCoV-POP): a population-based study. *Lancet*. 2020;396(10247):313-9.

446

447

## 448 **Funding**

449 KM acknowledges support from the Japan Society for the Promotion of Science

450 (JSPS) KAKENHI [Grant 20H03940 and 20KK0367], Japan Science and Technology

451 Agency (JST) SICORP[JPMJSC21U4], and from the Leading Initiative for Excellent

452 Young Researchers from the Ministry of Education, Culture, Sport, Science &

453 Technology of Japan. YS acknowledges support from JSPS KAKENHI [21K10416].

454 RM acknowledges support from JSPS KAKENHI [21K17250]. RO acknowledges

455 support from the JST, CREST [Grant JPMJCR20H1]. MW was supported by the

456 Platform Project for Supporting Drug Discovery and Life Science Research (BINDS)

457 from AMED [grant #JP18am0101076] and by direct funding from OIST.

458

## 459 **Authors' contributions**

460 YT conceived and directed the project. KM and YT designed the study with support from  
461 YS. KM conducted the analysis and wrote the first draft with support from YS, and TY.  
462 NT, RM and RO gave additional feedback on the first draft. YA, MN, SS, ST, SY, NT,  
463 HT, NC, SK, KK and SY collected the serological data and gave medical advice. M.M.,  
464 ELISA implementation, validation, analysis. M.M., S.S., N.S., ELISA execution. T.G.K.,  
465 N.S., protein expression. T.G.K., protein purification. C.B., workflow automation. M.N.  
466 provided samples and controls. M.N. and T.M, medical advice. M.C., advice on study  
467 design and ethics. M.W. OIST project creation and supervision. All authors reviewed the  
468 results and approved the final version of the manuscript.

469

## 470 **Ethics approval and consent to participate**

471 This study was approved by the ethics committees of Okinawa Prefectural  
472 Chubu Hospital (approval number: 24 in 2020), as well as all participating institutions  
473 (Okinawa Prefectural Chubu Hospital, Okinawa Prefectural Nambu Medical Center &  
474 Children's Medical Center, Naha City Hospital, Okinawa Prefectural Miyako Hospital,

475 Public Kumejima Hospital, OIST). This study was approved by the ethics committee of  
476 each of all six participating institutions. OIST HSR approval number HSR-2020-026.

477 All methods, including obtaining informed consent, were conducted in  
478 accordance with the Declaration of Helsinki and other relevant guidelines, including the  
479 Ethical Guidelines for Medical and Health Research Involving Human Subjects set forth  
480 by the Japanese government. Consent to publish the accumulated anonymized data has  
481 been obtained from all participants of the study upon enrollment.

482


### 483 **Consent for publication**

484 Not applicable.


### 485 **Competing interests**

486 The authors declare that they have no competing interests.


**A** Attack rate by age group  
Okinawa Main Island, As of July 15, 2020




**D** Attack rate by age group  
Remote islands, As of July 15, 2020




**B** Attack rate by age group  
Okinawa Main Island, As of Nov 15, 2020



**E** Attack rate by age group  
Remote islands, As of Nov 15, 2020



**C** Attack rate by age group  
Okinawa Main Island, As of Feb 15, 2021



**F** Attack rate by age group  
Remote islands, As of Feb 15, 2021




Figure3








Figure4

# Entire Japan



medRxiv preprint doi: <https://doi.org/10.1101/2022.03.02.22271759>; this version posted March 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Okinawa Prefecture

Okinawa Prefecture




Figure1










Figure2